Literature DB >> 3948132

Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy.

G Har-El, T Hadar, K Segal, R Levy, J Sidi.   

Abstract

Hurthle cell carcinoma is a rare thyroid cancer histologically related to the well-differentiated malignancies of the thyroid gland. This report presents the evaluation of 30 years experience in treating 17 patients (out of 549 thyroid cancer patients) with Hurthle cell carcinoma. All 17 patients were treated surgically. Six patients (35.3%) died of their thyroid disease. Survival rates for 10 and 15 years were 63.7% and 25%, respectively. These rates are above those of high-grade malignancies and below those of low-grade malignancies of the thyroid gland. Nonsurgical treatment, including radioactive iodine therapy, is disappointing; thus, initial radical surgery is recommended as the treatment of choice.

Entities:  

Mesh：

Year:  1986        PMID： 3948132     DOI： 10.1002/1097-0142(19860415)57:8<1613::aid-cncr2820570829>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  Unusual types of thyroid cancer.

Authors:  K B Ain
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Flow cytometric DNA measurements in benign and malignant Hürthle cell tumors of the thyroid.

Authors:  J J Ryan; I D Hay; C S Grant; L M Rainwater; G M Farrow; J R Goellner
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

3.  Surgical treatment of Hurthle cell tumors of the thyroid.

Authors:  Tzu-Chieh Chao; Jen-Der Lin; Miin-Fu Chen
Journal:  World J Surg       Date:  2005-02       Impact factor: 3.352

4.  Poorly differentiated oncocytic (hürthle cell) follicular carcinoma: an institutional experience.

Authors:  Shuting Bai; Zubair W Baloch; Teresa D Samulski; Kathleen T Montone; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

Review 5.  Hurthle cell tumours of the thyroid. Personal experience and review of the literature.

Authors:  A Barnabei; E Ferretti; R Baldelli; A Procaccini; G Spriano; M Appetecchia
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-12       Impact factor: 2.124

Review 6.  Prognostic indications for Hürthle cell cancer.

Authors:  Yevgeniya Kushchayeva; Quan-Yang Duh; Electron Kebebew; Orlo H Clark
Journal:  World J Surg       Date:  2004-11-11       Impact factor: 3.352

7.  The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hürthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans.

Authors:  T C Yen; H D Lin; C H Lee; S L Chang; S H Yeh
Journal:  Eur J Nucl Med       Date:  1994-09

Review 8.  Hürthle cell carcinoma.

Authors:  E Yutan; O H Clark
Journal:  Curr Treat Options Oncol       Date:  2001-08

Review 9.  My approach to oncocytic tumours of the thyroid.

Authors:  S L Asa
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

10.  Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Jatin P Shah; Alvaro Sanabria; Abir Al Ghuzlan; Carl E Silver; Ashok R Shaha; Peter Angelos; Dana M Hartl; Antti A Mäkitie; Kerry D Olsen; Randall P Owen; Gregory W Randolph; Ricard Simó; Ralph P Tufano; Luiz P Kowalski; Mark E Zafereo; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2021-08-22       Impact factor: 3.845
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.